Viehbacher hits out at Genzyme's "lack of realism"
This article was originally published in Scrip
Sanofi-Aventis's CEO Christopher Viehbacher has launched a scathing attack on Genzyme's repeated claims that the French firm's bid undervalued the biotech company and once again refused to raise his $69 per share offer. The pharma chief said that he "hadn't heard anything of substance that would cause [Sanofi-Aventis] to change its offer". However, declining third quarter sales figures may underscore the French giant's need to supplement its business, even if they undermine its ability to pay for the acquisition.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.